Our History
PrecisemAb is committed to offering the safest antibody therapy for patients.
  Our Mission
Our name, PrecisemAb, consists of ‘‘Precise’’ and ‘‘mAb’’
   which reflects our mission to enhance the safety of antibody drugs via our Universal Antibody Lock technology. We deeply believe that ‘‘only when treatments are both effective and safe would patients have the courage and persistence to fight illness. ’’

We care about people's health,
therefore we strive to create the safest treatment solutions for patients.
Universal Antibody Lock is just our first step......

History

PrecisemAb is established by Professor Tien-Lu Cheng, Dr. YunChi Lu, Dr. YiAn Cheng and Professor Cheng's lab members.
 
Professor Cheng has cultivated in antibody engineering for 25 years and his original ‘‘Universal Antibody Lock’’ technology can effectively enhance antibody’s selectivity for diseases and reduce adverse effects caused by antibody drugs. This innovative technology represents a revolutionary breakthrough in biotechnology industry.
 
Keeping the ideal of ‘‘giving back to society with self professions’’ in mind, PrecisemAb is committed to creating the safest antibody treatment for patients.

Milestones

Universal Antibody Lock invented

National Innovation Award
– 2nd place in student group

MOST–FITI  Program
– Outstanding Entrepreneurship Award

National Invention and Creation Award  
– Silver Award
 
Selected as Meet Taipei Exhibitor

–PrecisemAb officially established
–National Startup Competition: Champion in business incubation group
–Join DCB Taiwan Phoenix Accelerator
–Join MOST Taiwan  Germination Program
–Future Tech Award winner

–Complete technology transfer agreement with Kaohsiung Medical University
–Complete seed round of fundraising
–Got selected as one out of fourteen exhibitors in Taiwan pavillion, BIO US.
–Top 2 Asian region candidates of StartUp Stadium pitch contest held by BIO US.

–Awarded the Ministry of Economic Affairs Startup Value Creation Program(SVCP)
–Received a patent in Singapore for the Antibody Lock platform technology.
–Completed a three-month training at SkyDeck (a renowned accelerator in the United States. 

–Participated in Taiwan Demo Day in Silicon Valley, winning the "Best Pitch Award" and the "Most Market Potential Award."
–Joined the Taiwan-Berkeley Health Innovation Accelerator at the University of California, Berkeley.
–Collaborated with GlycoNex Inc. to develop the novel glycoantibody GNX201.
–Participated in the Bio International Convention in North America. 

Our Values

Science

With scientific spirit, we keep reflecting, experimenting, analyzing and innovating the most reliable solutions.

Innovation & Impact

We aim to make impact for a better human life through scientific innovation.

Share & Teamwork

We believe innovation comes from diversity. Therefore, we are keen to share and teamwork!
TOP